Highlights
- Market Cap
- $23.84M
- Enterprise Value
- $8.66M
- EPS (TTM)
- -$2.69
- Total Revenue (TTM)
- $7.55M
- EBITDA (TTM)
- -$8.65M
- Year Range
- $1.20 - $12.15
- Target Price
- $12.33
- ROA (TTM)
- -27.21%
- ROE (TTM)
- -45.37%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Evaxion Biotech AS, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Evaxion Biotech AS (EVAX) has returned -22.01% so far this year and 101.08% over the past 12 months.
Evaxion Biotech AS
- 1D
- -1.33%
- 1M
- 17.72%
- YTD
- -22.01%
- 6M
- -1.06%
- 1Y
- 101.08%
- 3Y*
- -59.62%
- 5Y*
- -57.41%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Feb 5, 2021, EVAX's average daily return is -0.08%, while the average monthly return is -4.57%.
Historically, 32% of months were positive and 68% were negative. The best month was May 2025 with a return of +60.8%, while the worst month was Dec 2024 at -49.1%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.
On a daily basis, EVAX closed higher 44% of trading days. The best single day was Jan 24, 2024 with a return of +113.4%, while the worst single day was Jan 22, 2024 at -45.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -33.33% | -0.63% | 17.72% | -22.01% | |||||||||
| 2025 | -41.92% | -20.98% | -4.64% | -17.30% | 60.78% | -0.41% | 9.39% | 2.61% | 36.73% | 52.93% | 3.22% | -19.63% | 12.85% |
| 2024 | -42.69% | -8.40% | -11.11% | 30.31% | -11.99% | -20.98% | -2.76% | 8.16% | 1.97% | -14.15% | -37.83% | -49.07% | -87.67% |
| 2023 | -9.30% | -4.35% | -26.62% | 11.50% | 20.63% | -13.82% | -5.34% | -33.06% | 0.35% | 34.45% | -28.66% | -14.18% | -61.37% |
| 2022 | -28.96% | -3.18% | -0.33% | -7.59% | -30.00% | -2.04% | 59.37% | -23.20% | 11.91% | -1.14% | -16.15% | -18.58% | -59.84% |
| 2021 | -29.42% | -15.47% | 20.85% | -5.47% | 14.84% | -30.23% | 20.93% | 47.63% | -21.06% | -38.76% | -5.15% | -55.31% |
Benchmark Metrics
Evaxion Biotech AS has an annualized alpha of -23.69%, beta of 0.60, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since February 08, 2021.
- This stock participated in 198.53% of S&P 500 Index downside but only -96.03% of its upside — more exposed to losses than it benefited from rallies.
- Beta of 0.60 may look defensive, but with R² of 0.01 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -23.69%
- Beta
- 0.60
- R²
- 0.01
- Upside Capture
- -96.03%
- Downside Capture
- 198.53%
Return for Risk
Risk / Return Rank
EVAX ranks 71 for risk / return — better than 71% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Evaxion Biotech AS (EVAX) and compare them to a chosen benchmark (S&P 500 Index).
| EVAX | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.83 | 0.90 | -0.06 |
Sortino ratioReturn per unit of downside risk | 1.97 | 1.39 | +0.58 |
Omega ratioGain probability vs. loss probability | 1.25 | 1.21 | +0.03 |
Calmar ratioReturn relative to maximum drawdown | 1.51 | 1.40 | +0.11 |
Martin ratioReturn relative to average drawdown | 2.73 | 6.61 | -3.87 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore EVAX risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Evaxion Biotech AS. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Evaxion Biotech AS was 99.79%, occurring on Apr 21, 2025. The portfolio has not yet recovered.
The current Evaxion Biotech AS drawdown is 99.41%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.79% | Nov 5, 2021 | 866 | Apr 21, 2025 | — | — | — |
| -47.74% | Feb 9, 2021 | 38 | Apr 5, 2021 | 150 | Nov 4, 2021 | 188 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Evaxion Biotech AS over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Evaxion Biotech AS is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for EVAX relative to other companies in the Biotechnology industry. Currently, EVAX has a P/S ratio of 1.4. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for EVAX in comparison with other companies in the Biotechnology industry. Currently, EVAX has a P/B value of 1.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |